Pipeline
We are developing differentiated peptide candidates to address unmet medical needs across therapeutic areas.

PARTNERS
PRECLINICAL
PHASE 1
PHASE 2
PHASE 3
REGISTRATION
Obesity
- PROGRAM Petrelintide
- Phase 2
- PROGRAM Dapiglutide
- Phase 1
- PROGRAM Survodutide
-
PARTNERS
- Phase 3
- PROGRAM ZP6590
- Preclinical
Congenital Hyperinsulinism
- PROGRAM Dasiglucagon: Continuous infusion
- Registration
Short Bowel Syndrome
- PROGRAM Glepaglutide
- Registration
Latest scientific publications
All Scientific publications-
Safety, Tolerability, and Clinical Effects of Petrelintide (ZP8396), A Long-acting Amylin Analog
-
Dapiglutide is a dual agonist on human GLP-1- and GLP-2-receptors with a biased and prolonged signaling profile at the GLP-1R
-
Petrelintide (ZP8396) selectively reduces intake of high fat diet in DIO rats
-
Petrelintide (ZP8396) significantly reduces fat mass while preserving lean mass in DIO rats

We are targeting a number of important therapeutic areas of high unmet need with our robust pipeline of differentiated candidates.
David Kendall
Chief Medical Officer, Zealand Pharma

